

# **AI in Drug Discovery Market (2nd Edition): Distribution by Drug Discovery Steps (Target Identification / Validation, Hit Generation / Lead Identification and Lead Optimization), Therapeutic Area (Oncological Disorders, CNS Disorders, Infectious Diseases, Respiratory Disorders, Cardiovascular Disorders, Endocrine Disorders, Gastrointestinal Disorders, Musculoskeletal Disorders, Immunological Disorders, Dermatological Disorders and Others) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035**

<https://marketpublishers.com/r/AA3C000D9AF1EN.html>

Date: September 2023

Pages: 387

Price: US\$ 4,799.00 (Single User License)

ID: AA3C000D9AF1EN

## **Abstracts**

The AI in drug discovery market is expected to reach USD 0.74 billion by 2022 anticipated to grow at a CAGR of 25% during the forecast period 2022-2035.

The journey of discovering and developing new therapeutic options faces significant hurdles, mainly due to a trial-and-error process resulting in a small fraction of leads becoming viable for clinical studies. It's estimated that roughly 90% of these prospects don't advance, leading to considerable financial strain. Bringing a new prescription drug to market typically spans 10 to 15 years and costs between \$1 to \$2 billion, with a substantial portion allocated to the discovery phase alone. To tackle these challenges, the pharmaceutical sector is turning to Artificial Intelligence (AI) tools to revolutionize drug discovery and development. AI, especially deep learning algorithms, can analyze

extensive clinical and biological data to guide modern drug discovery. These tools sift through scientific literature, electronic health records, and clinical trial data to offer insights for target identification, hit generation, and lead optimization.

At present, AI-powered tools such as deep learning, supervised and unsupervised learning, natural language processing, and machine learning are extensively utilized in healthcare for drug discovery. The objective is to enhance R&D efficiency and decrease clinical setbacks by forecasting safety and efficacy in early developmental phases. Around 210 AI drug discovery companies provide related services, with over \$10 billion invested in this sector over the last five years. Notably, half of this investment occurred in the last two years, signaling a growing interest. Additionally, there have been approximately 440 partnerships between industry and academic entities to advance AI-based solutions for drug discovery. The robust initiatives in this domain indicate potential market expansion in the forecasted period for stakeholders engaged in this emerging industry.

## Report Coverage

The report examines the AI in drug discovery market, focusing on drug discovery steps, therapeutic area and key geographies.

It analyzes factors impacting market growth, such as drivers, constraints, opportunities, and challenges.

Evaluation of potential benefits and hurdles within the market, providing insights into the competitive landscape for major industry players.

Revenue forecasts for market segments across six major regions.

Comprehensive analysis covering AI-centric companies specializing in drug discovery services, platforms, and tools. Parameters include company details like establishment year, employee count, headquarters location (North America, Europe, Asia-Pacific, Rest of the World), and categorization (service providers, technology providers, in-house players). Additionally, it encompasses AI technology types, drug discovery phases, types of drug molecules, and targeted therapeutic areas.

Detailed profiles of leading AI drug discovery companies in North America, Europe, and Asia-Pacific. Profiles encompass establishment year, employee

count, headquarters location, key executives, AI-based drug discovery technology portfolio, recent developments, and future prospects.

Examination of partnerships between stakeholders involved in AI-driven drug discovery from 2009-2022, covering various agreement types (research and development, technology access/utilization, acquisitions, licensing, joint ventures, mergers, service agreements) and analyzing partnership trends based on various parameters.

In-depth analysis of investments (grants, awards, financing rounds, IPOs, subsequent offerings) made in AI drug discovery companies from 2006-2022.

Evaluation of patents filed/granted from 2019 to February 2022, considering application year, geographical region, CPC symbols, emerging focus areas, applicant types, and leading players regarding intellectual property portfolios.

Qualitative assessment of competitive forces in the AI in drug discovery market, including threats for new entrants, bargaining power of drug developers, AI-based drug discovery companies, substitute technologies, and rivalry among existing competitors.

Detailed valuation analysis using a proprietary, multi-variable dependent valuation model to estimate the current net worth of AI drug discovery industry players.

Insightful analysis estimating potential cost savings associated with AI adoption in drug discovery across approximately 15 countries, considering pharmaceutical R&D expenditure, drug discovery budgets, and AI adoption across various discovery steps.

## Key Market Companies

Atomwise

BioSyntagma

Collaborations Pharmaceuticals

Cyclica

InveniAI

Recursion Pharmaceuticals

Valo Health

## Contents

### 1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines

### 2. EXECUTIVE SUMMARY

### 3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Artificial Intelligence
- 3.3. Subsets of AI
  - 3.3.1. Machine Learning
    - 3.3.1.1. Supervised Learning
    - 3.3.1.2. Unsupervised Learning
    - 3.3.1.3. Reinforced / Reinforcement Learning
    - 3.3.1.4. Deep Learning
    - 3.3.1.5. Natural Language Processing (NLP)
- 3.4. Data Science
- 3.5. Applications of AI in Healthcare
  - 3.5.1. Drug Discovery
  - 3.5.2. Disease Prediction, Diagnosis and Treatment
  - 3.5.3. Manufacturing and Supply Chain Operations
  - 3.5.4. Marketing
  - 3.5.5. Clinical Trials
- 3.6. AI in Drug Discovery
  - 3.6.1. Identification of Pathway and Target
  - 3.6.2. Identification of Hit or Lead
  - 3.6.3. Lead Optimization
  - 3.6.4. Synthesis of Drug-Like Compounds
- 3.7. Advantages of Using AI in the Drug Discovery Process
- 3.8. Challenges Associated with the Adoption of AI
- 3.9. Concluding Remarks

### 4. COMPETITIVE LANDSCAPE

- 4.1. Chapter Overview
- 4.2. AI-based Drug Discovery: Overall Market Landscape
  - 4.2.1. Analysis by Year of Establishment
  - 4.2.2. Analysis by Company Size
  - 4.2.3. Analysis by Location of Headquarters
  - 4.2.4. Analysis by Type of Company
  - 4.2.5. Analysis by Type of Technology
  - 4.2.6. Analysis by Drug Discovery Steps
  - 4.2.7. Analysis by Type of Drug Molecule
  - 4.2.8. Analysis by Drug Development Initiatives
  - 4.2.9. Analysis by Technology Licensing Option
  - 4.2.10. Analysis by Target Therapeutic Area
  - 4.2.11. Key Players: Analysis by Number of Platforms / Tools Available

## **5. COMPANY PROFILES: AI-BASED DRUG DISCOVERY PROVIDERS IN NORTH AMERICA**

- 5.1. Chapter Overview
- 5.2. Atomwise
  - 5.2.1. Company Overview
  - 5.2.2. AI-based Drug Discovery Technology Portfolio
  - 5.2.3. Recent Developments and Future Outlook
- 5.3. BioSyntagma
  - 5.3.1. Company Overview
  - 5.3.2. AI-based Drug Discovery Technology Portfolio
  - 5.3.3. Recent Developments and Future Outlook
- 5.4. Collaborations Pharmaceuticals
  - 5.4.1. Company Overview
  - 5.4.2. AI-based Drug Discovery Technology Portfolio
  - 5.4.3. Recent Developments and Future Outlook
- 5.5. Cyclica
  - 5.5.1. Company Overview
  - 5.5.2. AI-based Drug Discovery Technology Portfolio
  - 5.5.3. Recent Developments and Future Outlook
- 5.6. InveniAI
  - 5.6.1. Company Overview
  - 5.6.2. AI-based Drug Discovery Technology Portfolio
  - 5.6.3. Recent Developments and Future Outlook

## 5.7. Recursion Pharmaceuticals

### 5.7.1. Company Overview

### 5.7.2. AI-based Drug Discovery Technology Portfolio

### 5.7.3. Recent Developments and Future Outlook

## 5.8. Valo Health

### 5.8.1. Company Overview

### 5.8.2. AI-based Drug Discovery Technology Portfolio

### 5.8.3. Recent Developments and Future Outlook

## **6. COMPANY PROFILES: AI-BASED DRUG DISCOVERY SERVICE PROVIDERS IN EUROPE**

### 6.1. Chapter Overview

### 6.2. Aiforia Technologies

#### 6.2.1. Company Overview

#### 6.2.2. AI-based Drug Discovery Technology Portfolio

#### 6.2.3. Recent Developments and Future Outlook

### 6.3. Chemalive

#### 6.3.1. Company Overview

#### 6.3.2. AI-based Drug Discovery Technology Portfolio

#### 6.3.3. Recent Developments and Future Outlook

### 6.4. DeepMatter

#### 6.4.1. Company Overview

#### 6.4.2. AI-based Drug Discovery Technology Portfolio

#### 6.4.3. Recent Developments and Future Outlook

### 6.5. Exscientia

#### 6.5.1. Company Overview

#### 6.5.2. AI-based Drug Discovery Technology Portfolio

#### 6.5.3. Recent Developments and Future Outlook

### 6.6. MAbSilico

#### 6.6.1. Company Overview

#### 6.6.2. AI-based Drug Discovery Technology Portfolio

#### 6.6.3. Recent Developments and Future Outlook

### 6.7. Optibrium

#### 6.7.1. Company Overview

#### 6.7.2. AI-based Drug Discovery Technology Portfolio

#### 6.7.3. Recent Developments and Future Outlook

### 6.8. Sensyne Health

#### 6.8.1. Company Overview

6.8.2. AI-based Drug Discovery Technology Portfolio

6.8.3. Recent Developments and Future Outlook

## **7. COMPANY PROFILES: AI-BASED DRUG DISCOVERY SERVICE PROVIDERS IN ASIA PACIFIC**

7.1. Chapter Overview

7.2. 3BIGS

7.2.1. Company Overview

7.2.2. AI-based Drug Discovery Technology Portfolio

7.2.3. Recent Developments and Future Outlook

7.3. Gero

7.3.1. Company Overview

7.3.2. AI-based Drug Discovery Technology Portfolio

7.3.3. Recent Developments and Future Outlook

7.4. Insilico Medicine

7.4.1. Company Overview

7.4.2. AI-based Drug Discovery Technology Portfolio

7.4.3. Recent Developments and Future Outlook

7.5. KeenEye

7.5.1. Company Overview

7.5.2. AI-based Drug Discovery Technology Portfolio

7.5.3. Recent Developments and Future Outlook

## **8. PARTNERSHIPS AND COLLABORATIONS**

8.1. Chapter Overview

8.2. Partnership Models

8.3. AI-based Drug Discovery: Partnerships and Collaborations

8.3.1. Analysis by Year of Partnership

8.3.2. Analysis by Type of Partnership

8.3.3. Analysis by Year and Type of Partnership

8.3.4. Analysis by Target Therapeutic Area

8.3.5. Analysis by Focus Area

8.3.6. Analysis by Year of Partnership and Focus Area

8.3.7. Analysis by Type of Partner Company

8.3.8. Analysis by Type of Partnership and Type of Partner Company

8.3.9. Most Active Players: Analysis by Number of Partnerships

8.3.10. Analysis by Region



8.3.11.1. Intercontinental and Intracontinental Deals

8.3.11.2. International and Local Deals

## **9. FUNDING AND INVESTMENT ANALYSIS**

9.1. Chapter Overview

9.2. Types of Funding

9.3. AI-based Drug Discovery: Funding and Investments

9.3.1. Analysis of Number of Funding Instances by Year

9.3.2. Analysis of Amount Invested by Year

9.3.3. Analysis by Type of Funding

9.3.4. Analysis of Amount Invested and Type of Funding

9.3.5. Analysis of Amount Invested by Company Size

9.3.6. Analysis by Type of Investor

9.3.7. Analysis of Amount Invested by Type of Investor

9.3.8. Most Active Players: Analysis by Number of Funding Instances

9.3.9. Most Active Players: Analysis by Amount Invested

9.3.10. Most Active Investors: Analysis by Number of Funding Instances

9.3.11. Analysis of Amount Invested by Geography

9.3.11.1. Analysis by Region

9.3.11.2. Analysis by Country

## **10. PATENT ANALYSIS**

10.1. Chapter Overview

10.2. Scope and Methodology

10.3. AI-based Drug Discovery: Patent Analysis

10.3.1 Analysis by Application Year

10.3.2. Analysis by Geography

10.3.3. Analysis by CPC Symbols

10.3.4. Analysis by Emerging Focus Areas

10.3.5. Analysis by Type of Applicant

10.3.6. Leading Players: Analysis by Number of Patents

10.4. AI-based Drug Discovery: Patent Benchmarking

10.4.1. Analysis by Patent Characteristics

10.5. AI-based Drug Discovery: Patent Valuation

10.6. Leading Patents: Analysis by Number of Citations

## **11. PORTER'S FIVE FORCES ANALYSIS**

- 11.1. Chapter Overview
- 11.2. Methodology and Assumptions
- 11.3. Key Parameters
  - 11.3.1. Threats of New Entrants
  - 11.3.2. Bargaining Power of Drug Developers
  - 11.3.3. Bargaining Power of Companies Using AI for Drug Discovery
  - 11.3.4. Threats of Substitute Technologies
  - 11.3.5. Rivalry Among Existing Competitors
- 11.4. Concluding Remarks

## **12. COMPANY VALUATION ANALYSIS**

- 12.1. Chapter Overview
- 12.2. Company Valuation Analysis: Key Parameters
- 12.3. Methodology
- 12.4. Company Valuation Analysis: Roots Analysis Proprietary Scores

## **13. AI-BASED HEALTHCARE INITIATIVES OF TECHNOLOGY GIANTS**

- 13.1 Chapter Overview
  - 13.1.1. Amazon Web Services
  - 13.1.2. Microsoft
  - 13.1.3. Intel
  - 13.1.4. Alibaba Cloud
  - 13.1.5. Siemens
  - 13.1.6. Google
  - 13.1.7. IBM

## **14. COST SAVING ANALYSIS**

- 14.1. Chapter Overview
- 14.2. Key Assumptions and Methodology
- 14.3. Overall Cost Saving Potential Associated with Use of AI-based Solutions in Drug Discovery, 2022-2035
  - 14.3.1. Likely Cost Savings: Analysis by Drug Discovery Steps, 2022-2035
    - 14.3.1.1. Likely Cost Savings During Target Identification / Validation, 2022-2035
    - 14.3.1.2. Likely Cost Savings During Hit Generation / Lead Identification, 2022-2035
    - 14.3.1.3. Likely Cost Savings During Lead Optimization, 2022-2035

- 14.3.2. Likely Cost Savings: Analysis by Target Therapeutic Area, 2022-2035
  - 14.3.2.1. Likely Cost Savings for Drugs Targeting Oncological Disorders, 2022-2035
  - 14.3.2.2. Likely Cost Savings for Drugs Targeting Neurological Disorders, 2022-2035
  - 14.3.2.3. Likely Cost Savings for Drugs Targeting Infectious Diseases, 2022-2035
  - 14.3.2.4. Likely Cost Savings for Drugs Targeting Respiratory Disorders, 2022-2035
  - 14.3.2.5. Likely Cost Savings for Drugs Targeting Cardiovascular Disorders, 2022-2035
  - 14.3.2.6. Likely Cost Savings for Drugs Targeting Endocrine Disorders, 2022-2035
  - 14.3.2.7. Likely Cost Savings for Drugs Targeting Gastrointestinal Disorders, 2022-2035
  - 14.3.2.8. Likely Cost Savings for Drugs Targeting Musculoskeletal Disorders, 2022-2035
  - 14.3.2.9. Likely Cost Savings for Drugs Targeting Immunological Disorders, 2022-2035
  - 14.3.2.10. Likely Cost Savings for Drugs Targeting Dermatological Disorders, 2022-2035
  - 14.3.2.11. Likely Cost Savings for Drugs Targeting Other Disorders, 2022-2035
- 14.3.3. Likely Cost Savings: Analysis by Geography, 2022-2035
  - 14.3.3.1. Likely Cost Savings in North America, 2022-2035
  - 14.3.3.2. Likely Cost Savings in Europe, 2022-2035
  - 14.3.3.3. Likely Cost Savings in Asia Pacific, 2022-2035
  - 14.3.3.4. Likely Cost Savings in MENA, 2022-2035
  - 14.3.3.5. Likely Cost Savings in Latin America, 2022-2035
  - 14.3.3.6. Likely Cost Savings in Rest of the World, 2022-2035

## **15. MARKET FORECAST**

- 15.1. Chapter Overview
- 15.2. Key Assumptions and Methodology
- 15.3. Global AI-based Drug Discovery Market, 2022-2035
  - 15.3.1. AI-based Drug Discovery Market: Distribution by Drug Discovery Steps, 2022-2035
    - 15.3.1.1. AI-based Drug Discovery Market for Target Identification / Validation, 2022-2035
    - 15.3.1.2. AI-based Drug Discovery Market for Hit Generation / Lead Identification, 2022-2035
    - 15.3.1.3. AI-based Drug Discovery Market for Lead Optimization, 2022-2035
  - 15.3.2. AI-based Drug Discovery Market: Distribution by Target Therapeutic Area, 2022-2035

- 15.3.2.1. AI-based Drug Discovery Market for Oncological Disorders, 2022-2035
- 15.3.2.2. AI-based Drug Discovery Market for Neurological Disorders, 2022-2035
- 15.3.2.3. AI-based Drug Discovery Market for Infectious Diseases, 2022-2035
- 15.3.2.4. AI-based Drug Discovery Market for Respiratory Disorders, 2022-2035
- 15.3.2.5. AI-based Drug Discovery Market for Cardiovascular Disorders, 2022-2035
- 15.3.2.6. AI-based Drug Discovery Market for Endocrine Disorders, 2022-2035
- 15.3.2.7. AI-based Drug Discovery Market for Gastrointestinal Disorders, 2022-2035
- 15.3.2.8. AI-based Drug Discovery Market for Musculoskeletal Disorders, 2022-2035
- 15.3.2.9. AI-based Drug Discovery Market for Immunological Disorders, 2022-2035
- 15.3.2.10. AI-based Drug Discovery Market for Dermatological Disorders, 2022-2035
- 15.3.2.11. AI-based Drug Discovery Market for Other Disorders, 2022-2035
- 15.3.3. AI-based Drug Discovery Market: Distribution by Geography, 2022-2035
  - 15.3.3.1. AI-based Drug Discovery Market in North America, 2022-2035
    - 15.3.3.1.1. AI-based Drug Discovery Market in the US, 2022-2035
    - 15.3.3.1.2. AI-based Drug Discovery Market in Canada, 2022-2035
  - 15.3.3.2. AI-based Drug Discovery Market in Europe, 2022-2035
    - 15.3.3.2.1. AI-based Drug Discovery Market in the UK, 2022-2035
    - 15.3.3.2.2. AI-based Drug Discovery Market in France, 2022-2035
    - 15.3.3.2.3. AI-based Drug Discovery Market in Germany, 2022-2035
    - 15.3.3.2.4. AI-based Drug Discovery Market in Spain, 2022-2035
    - 15.3.3.2.5. AI-based Drug Discovery Market in Italy, 2022-2035
    - 15.3.3.2.6. AI-based Drug Discovery Market in Rest of Europe, 2022-2035
  - 15.3.3.3. AI-based Drug Discovery Market in Asia Pacific, 2020-2035
    - 15.3.3.3.1. AI-based Drug Discovery Market in China, 2022-2035
    - 15.3.3.3.2. AI-based Drug Discovery Market in India, 2022-2035
    - 15.3.3.3.3. AI-based Drug Discovery Market in Japan, 2022-2035
    - 15.3.3.3.4. AI-based Drug Discovery Market in Australia, 2022-2035
    - 15.3.3.3.5. AI-based Drug Discovery Market in South Korea, 2022-2035
  - 15.3.3.4. AI-based Drug Discovery Market in MENA, 2022-2035
    - 15.3.3.4.1. AI-based Drug Discovery Market in Saudi Arabia, 2022-2035
    - 15.3.3.4.2. AI-based Drug Discovery Market in UAE, 2022-2035
    - 15.3.3.4.3. AI-based Drug Discovery Market in Iran, 2022-2035
  - 15.3.3.5. AI-based Drug Discovery Market in Latin America, 2022-2035
    - 15.3.3.5.1. AI-based Drug Discovery Market in Argentina, 2022-2035
  - 15.3.3.6. AI-based Drug Discovery Market in Rest of the World, 2022-2035

## **16. CONCLUSION**

## **17. EXECUTIVE INSIGHTS**

## 17.1. Chapter Overview

### 17.2. Aigenpulse

#### 17.2.1. Company Snapshot

#### 17.2.2. Interview Transcript: Steve Yemm (Chief Commercial Officer) and Satnam Surae (Chief Product Officer)

### 17.3. Cloud Pharmaceuticals

#### 17.3.1. Company Snapshot

#### 17.3.2. Interview Transcript: Ed Addison (Co-founder, Chairman and Chief Executive Officer)

### 17.4. DEARGEN

#### 17.4.1. Company Snapshot

#### 17.4.2. Interview Transcript: Bo Ram Beck (Head Researcher)

### 17.5. Intelligent Omics

#### 17.5.1. Company Snapshot

#### 17.5.2. Interview Transcript: Simon Haworth (Chief Executive Officer)

### 17.6. Pepticom

#### 17.6.1. Company Snapshot

#### 17.6.2. Interview Transcript: Immanuel Lerner (Chief Executive Officer, Co-Founder)

### 17.7. Sage-N Research

#### 17.7.1. Company Snapshot

#### 17.7.2. Interview Transcript: David Chiang (Chairman)

## **18. APPENDIX I: TABULATED DATA**

## **19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS**

## I would like to order

Product name: AI in Drug Discovery Market (2nd Edition): Distribution by Drug Discovery Steps (Target Identification / Validation, Hit Generation / Lead Identification and Lead Optimization), Therapeutic Area (Oncological Disorders, CNS Disorders, Infectious Diseases, Respiratory Disorders, Cardiovascular Disorders, Endocrine Disorders, Gastrointestinal Disorders, Musculoskeletal Disorders, Immunological Disorders, Dermatological Disorders and Others) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

Product link: <https://marketpublishers.com/r/AA3C000D9AF1EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA3C000D9AF1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970